Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
about
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survivalCirculating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancerMesothelin targeted cancer immunotherapyHigh mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinomaAntigen-specific immunotherapy of cervical and ovarian cancerRecognition of Mesothelin by the Therapeutic Antibody MORAb-009: STRUCTURAL AND MECHANISTIC INSIGHTSA novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.Pathogenesis of ovarian cancer: clues from selected overexpressed genes.Mesothelin Immunotherapy for Cancer: Ready for Prime Time?Mesothelin expression is associated with poor outcomes in breast cancer.Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survivalGeneration and characterization of an ascitogenic mesothelin-expressing tumor model.Control of human mesothelin-expressing tumors by DNA vaccines.A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune inductionRedirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptorOptimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancerCharacterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics.Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancer.Mesothelin expression is a prognostic factor in cholangiocellular carcinoma.The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1.Autoantibodies as biomarkers for ovarian cancer.Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunityMesothelin expression and survival outcomes in triple receptor negative breast cancer.Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity.CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.ERC/mesothelin is expressed in human gastric cancer tissues and cell lines.Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.Mesothelin Expression in Gastric Adenocarcinoma and Its Relation to Clinical OutcomesSystematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.Mesothelin expression correlates with prolonged patient survival in gastric cancer.A new anti-mesothelin antibody targets selectively the membrane-associated form.The Impact of Mesothelin in the Ovarian Cancer Tumor Microenvironment
P2860
Q24320324-9C2628D9-5A23-4FF2-804E-C916786E40F4Q24651062-2E0AD84F-9233-4916-B0C2-432694D31324Q24656242-DC682CCC-83AC-40D3-80BA-A86C04DDF998Q24658024-49D90A7F-5E5C-48EB-8108-7383CB8A0B9FQ27488697-26245182-8D85-40F1-9B6B-63F62EF053C0Q27670713-44646622-F19D-46BD-93EB-E217C3A579B3Q30478956-E5E1BE55-90A4-42D0-A883-F541388AE9F8Q33651139-01311B24-3A94-4B44-BB3F-406F8A439702Q33816551-5FC20FE7-0545-4FAD-8B78-FE00AE86C8DCQ34669372-5F1FA963-8006-4542-A30C-603AB363C7DAQ34703865-C2011D85-7BC7-49A1-A45A-E657282297B4Q35236067-E8B74C55-755E-4D9D-B7A4-0413C58A410DQ35238497-F63148D5-FD80-45EF-874E-3CDFBFF03B50Q35787391-B3B4AFB4-D323-410C-ADFF-196F203A9C19Q35802193-995A6A49-9CE6-4A18-9147-35D4C6541736Q35837949-54DD714B-62A2-4BE7-85D2-9213DC08661BQ36075289-8ACBD5E2-7449-48BF-A14C-34AA8F590E86Q36143556-AC076B29-CA3A-4EF2-8AD8-4A3F00A26411Q36184966-D9411890-88BD-4301-A68B-83856C6D841FQ36976473-FB53B201-AF45-48A5-B719-B00D01FD566BQ37044754-336CBB39-600E-437D-999F-37E8A3383C88Q37066492-640CEA61-AD9C-4718-990E-3D05A1A8E6C7Q37224335-10E353DF-85EC-4226-BE37-E6D982979B90Q37270601-98B224C7-77D4-42BD-B3D3-78CA0C20E874Q37286656-88AD7D79-BA42-4D60-955A-B3AEBE18A374Q37339008-8E722B8F-4890-4B45-A41C-4DE2D098B55EQ37342848-86F133E2-C96B-46BC-8F45-A293163C6B40Q37371532-799831A1-5658-4EC7-B7CE-A3FFC2D36B58Q37404580-F8EECF6F-4BA7-4434-9EA8-A3BA3657AB59Q38286381-3EC5FB0B-08B2-41BB-AA49-B5E679CB1571Q38761712-17270F52-A3FD-4341-8A58-1A24CB76C31BQ41992584-6EC86E6F-62EC-4231-B0BE-F2EB245E70D4Q45849410-09C34BDD-0F81-4AA0-AAF2-26785DC3B7FAQ51019702-221B2FE9-88FB-4D3A-A103-AB96247FB2B2Q51082110-362DEB68-8AD6-460C-8FF8-C43C83D3132CQ58726271-40162A9A-61A4-4FB5-B253-60F4AFA0ED85
P2860
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Diffuse mesothelin expression ...... l in ovarian serous carcinoma.
@ast
Diffuse mesothelin expression ...... l in ovarian serous carcinoma.
@en
type
label
Diffuse mesothelin expression ...... l in ovarian serous carcinoma.
@ast
Diffuse mesothelin expression ...... l in ovarian serous carcinoma.
@en
prefLabel
Diffuse mesothelin expression ...... l in ovarian serous carcinoma.
@ast
Diffuse mesothelin expression ...... l in ovarian serous carcinoma.
@en
P2093
P1476
Diffuse mesothelin expression ...... l in ovarian serous carcinoma.
@en
P2093
Chih-Yi Hsu
Ie-Ming Shih
Richard Roden
Tian-Li Wang
Tsui-Lien Mao
P304
P356
10.1158/1078-0432.CCR-05-1397
P407
P433
P577
2006-02-01T00:00:00Z